Cormorant Asset Management’s Quince Therapeutics QNCX Stock Holding History

Cormorant Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Buy	+5,498	New	+$126K	0.01%	50

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cormorant Asset Management's QNCX Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 5,498 shares worth $100K. The stake represents 0.01% of the portfolio and ranks #50 among its holdings.

25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Cormorant Asset Management held 5,498 shares of Quince Therapeutics worth $100K as of Q2 2026.
Quince Therapeutics was a new Cormorant Asset Management position in Q2 2026.
Quince Therapeutics made up 0.01% of Cormorant Asset Management's portfolio in Q2 2026, its #50 holding.
25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.